Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
"Wellness isn't about one-time fixes
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Researchs GLP-1 comparative effectiveness study, initially shared more than a year ago on November 27, 2023 and published earlier this year in JAMA Internal Medicine
This is a legal concept that says the federal regulations (usually set by the FDA) kept the company from making changes to its drugs warning label
Many commercial insurance plans treat weight loss medications as an "optional" benefit , allowing employers to exclude them to save money
Despite these promising outcomes, notable gaps remain in the research
Transl Res
)
